Table 3.

Baseline (pretreatment) integrated area under the concentration curve of gadolinium contrast at 90 (AUC 90) and 180 (AUC 180) s from the start of contrast enhancement

	AUC 90 > 17.1 (n = 14)	AUC 90 ≤ 17.1 (n = 14)	P	AUC 180 > 34.2 (n = 14)	AUC 180 ≤ 34.2 (n = 14)	P
Response rate	8 (57.1%)	4 (28.6%)	0.13	7 (50%)	5 (35.7%)	0.44
Progression-free survival	7.4 months	6.8 months	0.077	7.2 months	7.3 months	0.77
Hepatic progression-free survival	11.5 months	7.5 months	0.28	11.5 months	7.5 months	0.18
Disease-specific survival	35.1 months	19.1 months	0.019	35.1 months	19.1 months	0.002
Survival >18 months	12 (85.7.3%)	9 (64.3%)	0.19	13 (92.9%)	8 (57.1%)	0.029
Survival >24 months	10 (71.4%)	5 (35.7%)	0.058	10 (71.4%)	5 (35.7%)	0.058

Patients were stratified around the median values for both variables. Region of interest analyses were carried out. Units for AUC—mM·s.

AUC, area under the concentration curve.